Gain Therapeutics (NASDAQ:GANX) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a report released on Thursday, Benzinga reports. HC Wainwright currently has a $9.00 price target on the stock.

A number of other analysts also recently issued reports on the stock. Chardan Capital reaffirmed a buy rating and set a $6.00 price objective on shares of Gain Therapeutics in a report on Wednesday, March 27th. Oppenheimer reaffirmed an outperform rating and set a $9.00 price objective on shares of Gain Therapeutics in a report on Tuesday, April 23rd.

Gain Therapeutics Stock Down 1.3 %

GANX opened at $3.03 on Thursday. The company has a 50 day moving average of $3.97 and a 200 day moving average of $3.44. The company has a market cap of $49.15 million, a PE ratio of -1.77 and a beta of 0.43. Gain Therapeutics has a 12 month low of $2.00 and a 12 month high of $5.65. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.04.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings results on Tuesday, March 26th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.03. On average, sell-side analysts expect that Gain Therapeutics will post -1.22 EPS for the current year.

Insider Buying and Selling

In other Gain Therapeutics news, Director Jeffrey Scott Riley bought 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 28th. The shares were bought at an average price of $3.86 per share, for a total transaction of $115,800.00. Following the transaction, the director now directly owns 30,000 shares in the company, valued at $115,800. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 11.00% of the stock is owned by corporate insiders.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.